> Santhera's IPO raised $71 million (88.5 million Swiss Francs) after shares began trading today. Report
> The FDA has approved NovaDel's NitroMist for angina. Par Pharmaceuticals holds the North American rights to the drug. "The FDA's approval of NitroMist is a major milestone for NovaDel, as it represents the first approval of a drug using our proprietary oral spray technology," said CEO Jan Egberts. Release
> Adventrx is selling $40 million in shares. Release
> Some analysts are giving Vertex the edge in the race to get a new drug approved for hepatitis C. Report
> The EMEA has given Bradmer Pharmaceuticals' Neuradiab orphan drug status for the treatment of glioblastoma multiforme. Release
> PTC Therapeutics is touting positive Phase II data for its cystic fibrosis therapy PTC124. Release
> Avanir is selling $15 million in common stock. Release
> The FDA is questioning the off-label use of Cephalon's painkiller Actiq, which is approved only for use in treating cancer pain. Report
> Take a peek at the Motley Fool's Biotech Haunted House...if you dare. Report
And Finally... Chinese officials are disputing reports that a new strain of bird flu has emerged in the country. Report (WSJ sub. req.)